COMMUNIQUÉS West-GlobeNewswire

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer
09/03/2026
persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed Giredestrant plus palbociclib was well [...]
TimelyCare Launches TimelyPulse to Help Colleges Spot Struggling Students Before It’s Too Late
09/03/2026
New proactive engagement solution aims to close the gap between early signals and meaningful follow-through Fort Worth, TX, March 09, 2026 (GLOBE NEWSWIRE) -- Colleges and universities have invested heavily in early [...]
Zelluna announces collaboration with Etcembly for AI-enabled TCR engineering
09/03/2026
Oslo, Norway, 09 March 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced a [...]
TME PHARMA PROLONGE SA CAPACITÉ FINANCIÈRE À PLUS DE 12 MOIS
09/03/2026
TME PHARMA PROLONGE SA CAPACITÉ FINANCIÈRE À PLUS DE 12 MOIS Berlin, Allemagne, 9 mars 2025, 8 h 00 CET – TME Pharma N.V. (Euronext Growth Paris : ALTME), une société de biotechnologie au stade clinique spécialisée dans [...]
TME Pharma extends financial runway to over 12 months
09/03/2026
TME Pharma extends financial runway to over 12 months Berlin, Germany , March 9, 2025, 08.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development [...]
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
08/03/2026
- New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history - - Data expand on previously reported results demonstrating that z-rostudirsen [...]
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)
08/03/2026
- HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 - - 48-week trial will enroll approximately 150 individuals, and first sites are now open for enrollment - - Primary [...]
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
08/03/2026
NEW YORK and WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the [...]
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
08/03/2026
Please see enclosed pdf. Attachment 08032026_trading_in_shares_GL
Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026
08/03/2026
VANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development [...]
AIM ImmunoTech Announces Closing of its Rights Offering
07/03/2026
OCALA, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead [...]
MagnesiumFreeze Sciatic Nerve Claims Evaluated: Consumer Research Report Examines Magnesium Niacinamide Relief Topical Cream Ingredients, NAD+ Science, and Sciatic Nerve Support Discussions
07/03/2026
A 2026 informational consumer research report examining MagnesiumFreeze (Magnesium Niacinamide Relief) topical nerve support claims, ingredient research context, pricing disclosures, and verification considerations for [...]
Spyre Therapeutics Announces Grants of Inducement Awards
06/03/2026
WALTHAM, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations [...]
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/03/2026
BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on March 3, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera [...]
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/03/2026
PRINCETON, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, [...]
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
07/03/2026
Each Lisata stockholder to receive $5.00 per share in cash payable at closing plus one contingent value right for a potential additional cash payment of $1.00 per share Board of directors unanimously approved the [...]
Crescent Biopharma Announces Grants of Inducement Awards
06/03/2026
WALTHAM, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies [...]
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/03/2026
BOSTON, March 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that, effective February 2, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non- [...]
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/03/2026
NAARDEN, the Netherlands and MIAMI, March 06, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral [...]

Pages